| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.94 | $88.17 (0%) | 🛒 Add to cart |
| 60 | $2.52 | $176.34 $151.29 (14%) | 🛒 Add to cart |
| 90 | $2.38
Best per pill | $264.51 $214.42 (19%) | 🛒 Add to cart |
Synonyms | |||
Similar products
More info:
Tizanidine: Effective Spasticity Management for Neurological Conditions - Evidence-Based Review
Tizanidine hydrochloride is a centrally-acting alpha-2 adrenergic agonist that functions as a skeletal muscle relaxant. Available in both immediate-release and extended-release formulations, this medication occupies a unique therapeutic niche for managing spasticity across various neurological conditions. Unlike peripherally-acting agents that target muscles directly, tizanidine works at the spinal cord and brain levels to modulate neurotransmitter release, effectively reducing excessive muscle tone without causing significant muscle weakness at appropriate doses. The drug’s development stemmed from research into clonidine-like compounds, though tizanidine demonstrates more selective muscle relaxant properties with fewer cardiovascular effects.
baclofen
Baclofen represents one of those fascinating clinical tools that sits at the intersection of neurology, addiction medicine, and rehabilitation. As a GABA-B receptor agonist, this medication has transformed spasticity management while simultaneously creating one of medicine’s most controversial off-label applications. I still remember my first complex case – a 38-year-old multiple sclerosis patient named Sarah whose severe lower extremity spasms prevented basic self-care. We started her on 5mg TID, and within two weeks, she could transfer independently from wheelchair to bed.
baclosign
Baclosign represents one of those rare clinical tools that fundamentally changes how we approach spasticity management. When I first encountered the prototype six years ago during a neurology conference in Berlin, I’ll admit I was skeptical—another “revolutionary” device that would likely collect dust in a storage closet. But what struck me was the elegant simplicity of the concept: using precisely calibrated vibrational frequencies to modulate spinal reflex arcs without systemic medication side effects.
ciplox
Ciprofloxacin, marketed under brand names like Ciplox, remains one of the most widely prescribed fluoroquinolone antibiotics globally. Its broad-spectrum activity against Gram-positive and Gram-negative bacteria made it a workhorse in our infectious disease arsenal for decades. I remember during my residency in the late 90s, we’d reach for it almost reflexively for complicated UTIs, certain respiratory infections, and even some gastrointestinal bugs when first-line options failed. The mechanism—inhibition of bacterial DNA gyrase and topoisomerase IV—was elegant in its specificity, or so we thought at the time.
Cipro: Effective Antibiotic Treatment for Bacterial Infections - Evidence-Based Review
Ciprofloxacin, commonly known as Cipro, is a broad-spectrum fluoroquinolone antibiotic that has been a cornerstone in treating serious bacterial infections since its introduction in the 1980s. As a synthetic chemotherapeutic agent, it works by inhibiting bacterial DNA gyrase and topoisomerase IV, effectively halting DNA replication in susceptible organisms. Its broad activity against Gram-negative bacteria and some Gram-positive pathogens made it particularly valuable for respiratory, urinary tract, and gastrointestinal infections, though its use has become more restricted in recent years due to safety concerns.
flexeril
Flexeril is a centrally-acting skeletal muscle relaxant with a complex pharmacological profile that continues to intrigue clinicians decades after its introduction. Structurally related to tricyclic antidepressants, cyclobenzaprine’s primary mechanism involves reducing tonic somatic motor activity at the brainstem level through noradrenergic modulation rather than direct peripheral action on muscle fibers. This distinction is clinically significant - we’re not dealing with a neuromuscular blocker but rather a CNS modulator that interrupts the reflex arc contributing to muscle spasm.
lioresal
Baclofen, marketed under the brand name Lioresal among others, is a medication that has fundamentally changed how we manage severe spasticity. It’s a GABA derivative that acts as a selective agonist for GABA-B receptors, primarily used to treat muscle spasticity in conditions like multiple sclerosis, spinal cord injuries, and cerebral palsy. Unlike many newer agents, its mechanism is well-understood and its efficacy is backed by decades of clinical use. Lioresal: Effective Spasticity Management for Neurological Conditions - Evidence-Based Review 1.
Luvox: Effective OCD and Anxiety Symptom Management - Evidence-Based Review
Fluvoxamine, marketed under the brand name Luvox among others, is a selective serotonin reuptake inhibitor (SSRI) primarily prescribed for obsessive-compulsive disorder (OCD) and off-label for several anxiety-related conditions. It works by increasing serotonin levels in the brain, which helps regulate mood, anxiety, and obsessive thoughts. Available in tablet and extended-release capsule forms, it’s a cornerstone in psychopharmacology for its efficacy and relatively well-tolerated profile compared to older antidepressants. 1. Introduction: What is Luvox?
Noroxin: Targeted Antibacterial Therapy for Urinary Tract Infections - Evidence-Based Review
Norfloxacin, a synthetic broad-spectrum fluoroquinolone antibiotic, has been a cornerstone in treating specific bacterial infections since its introduction. It works by inhibiting bacterial DNA gyrase, effectively halting bacterial replication. Primarily used for complicated and uncomplicated urinary tract infections (UTIs), its role has evolved with growing antimicrobial resistance patterns. Understanding its pharmacokinetics, spectrum of activity, and appropriate clinical applications is essential for modern antimicrobial stewardship. 1. Introduction: What is Noroxin? Its Role in Modern Medicine Noroxin represents the brand name for norfloxacin, a second-generation fluoroquinolone antibiotic first approved in the 1980s.